pRAD50: A Novel and Clinically Applicable Pharmacodynamic Biomarker of Both ATM and ATR Inhibition Identified Using Mass Spectrometry and Immunohistochemistry

British Journal of Cancer - United Kingdom
doi 10.1038/s41416-018-0286-4
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

From Biomarker Discovery to Proteomic Validation Using Mass Spectrometry

Acta Ophthalmologica
MedicineOphthalmology
2018English

Anti-Tumor Effect of Inhibition of DNA Damage Response Proteins, ATM and ATR, in Endometrial Cancer Cells

Cancers
Cancer ResearchOncology
2019English

Measurement of Cyclooxygenase Inhibition Using Liquid Chromatography–tandem Mass Spectrometry

Journal of Pharmaceutical and Biomedical Analysis
Clinical BiochemistryDrug DiscoveryAnalytical ChemistrySpectroscopyPharmaceutical Science
2011English

Rapid Activation of ATR by Ionizing Radiation Requires ATM and Mre11

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2006English

Cell Cycle Checkpoint Signaling Through the ATM and ATR Kinases

Genes and Development
GeneticsDevelopmental Biology
2001English

Twelve Novel Atm Mutations Identified in Chinese Ataxia Telangiectasia Patients

NeuroMolecular Medicine
Molecular NeuroscienceNeurologyMolecular MedicineCellular
2013English

Straightforward and Highly Efficient Strategy for Hepatocellular Carcinoma Glycoprotein Biomarker Discovery Using a Nonglycopeptide-Based Mass Spectrometry Pipeline

English

Structural Characterization of Anticancer Drug Paclitaxel and Its Metabolites Using Ion Mobility Mass Spectrometry and Tandem Mass Spectrometry

Journal of the American Society for Mass Spectrometry
Structural BiologySpectroscopy
2015English

Clinically Applicable Deep Learning Algorithm Using Quantitative Proteomic Data

English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy